Gossamer Bio (GOSS) Stock Price
Gossamer Bio Price
For Gossamer Bio, the net margin of -351.5% is down versus -49.3% a few years ago. The consensus 12-month price target for Gossamer Bio is 9.18 USD, about 14.3% below where the stock trades today. Of 16 analysts, 14 rate the stock a buy — an overall Buy consensus.
Gossamer Bio stock price
Gossamer Bio business model & stock analysis
Frequently asked questions about Gossamer Bio
The business model of Gossamer Bio Inc revolves around the development and commercialization of innovative therapeutics for patients with severe and life-threatening diseases. As an emerging biopharmaceutical company, Gossamer Bio focuses on discovering and advancing its pipeline of novel, differentiated drug candidates. With a commitment to scientific excellence and strategic partnerships, Gossamer Bio aims to address unmet medical needs by bringing transformative therapies to patients worldwide.
Gossamer Bio Inc is primarily active in the biotechnology industry.
The main competitors of Gossamer Bio Inc in the market are Amgen Inc, Merck & Co. Inc, and Vertex Pharmaceuticals Incorporated.
Gossamer Bio Inc is a biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics to treat immune-related diseases. Founded in 2015, Gossamer Bio has swiftly emerged as a leader in the biotech industry. With a strong emphasis on innovative research and strategic partnerships, the company aims to address various unmet medical needs. Gossamer Bio's dedicated team of experts strives to enhance patients' lives by advancing the development of novel treatments. With a commitment to scientific excellence, Gossamer Bio Inc remains at the forefront of cutting-edge therapies to improve patient outcomes and revolutionize the field of immunology.
Gossamer Bio Inc has achieved several significant milestones in its journey. Firstly, the company successfully completed its initial public offering (IPO) in February 2019, raising substantial funds to support its operations and growth. Additionally, Gossamer Bio Inc has made significant progress in its clinical pipeline, with the initiation of Phase 2 studies for its lead product candidates in areas such as asthma, chronic rhinosinusitis, and inflammatory bowel disease. These milestones demonstrate the company's commitment to advancing innovative therapies that address unmet medical needs. Gossamer Bio Inc's ongoing efforts and achievements position it as a prominent player in the biopharmaceutical industry.
Gossamer Bio Inc is primarily present in the United States.
Gossamer Bio Inc represents values of innovation, collaboration, and dedication to improving patient outcomes. The company's corporate philosophy revolves around developing and advancing novel therapeutic solutions to address significant unmet medical needs. With a focus on precision medicine and leveraging cutting-edge technology, Gossamer Bio Inc aims to transform the lives of patients by developing innovative treatments for complex diseases. By prioritizing patient-centered approaches and fostering partnerships within the scientific and medical communities, Gossamer Bio Inc strives to make a meaningful impact on healthcare and drive positive change for patients worldwide.
Analysts currently set an average price target of 9.56 USD for the Gossamer Bio stock (median: 9.18 USD), implying -10.7 % versus the latest price. The consensus is based on 16 analyst ratings.
14 analysts currently rate the Gossamer Bio stock: 9 recommend buying, 4 holding and 1 selling. For 2026, analysts expect Gossamer Bio to generate revenue of 35.86 M USD and earnings per share of -15.75 USD.
Converted at the current exchange rate, the Gossamer Bio share trades at 9.52 EUR (10.71 USD).
The Gossamer Bio share (GOSS) is listed on 4 stock exchanges, including: NASDAQ (GOSS), Frankfurt (4GB.F), München (4GB.MU), Düsseldorf (4GB.DU).
Gossamer Bio Inc is an American biotechnology company that is dedicated to the discovery and development of new therapeutics for specific diseases. The company was founded in 2018 by an experienced team of executives and experts in the biotechnology industry. Gossamer Bio is headquartered in San Diego, California and currently employs over 100 employees. The business model of Gossamer Bio can be divided into three main areas: research and development, clinical trials, and marketing. The research and development division focuses on identifying new drug candidates for diseases such as respiratory diseases, inflammatory diseases, oncology, and infectious diseases. The company utilizes state-of-the-art technologies and platforms to identify and optimize promising candidates before testing them in clinical trials. Clinical trials play a crucial role in evaluating the efficacy and safety of drug candidates. Gossamer Bio conducts carefully planned studies to achieve scientific validation of the therapeutics. The company also utilizes a network of leading clinical facilities and research centers to conduct studies and collect data. This helps the company evaluate the efficacy and safety of the therapeutics and submit the best recommendation for drug approval to regulatory authorities. Once the clinical trials are completed and the therapeutics are approved, the company moves into the marketing phase. Gossamer Bio offers its therapeutics directly to patients and healthcare professionals through distribution and marketing channels. The company also utilizes partnerships and licensing agreements to enhance access to various markets and regions. This helps the company minimize distribution costs and maximize the reach of its therapeutics. Gossamer Bio already has several promising drug candidates in its pipeline, including GB001, GB002, GB004, and GB1275. Most of them are targeted towards respiratory diseases such as asthma, chronic lung disease, and idiopathic pulmonary fibrosis. GB001 is an inhaled breast cancer medication, while GB1275 targets various solid tumors including pancreatic cancer. Overall, Gossamer Bio has a strong business model that focuses on research and development, clinical trials, and marketing. As an innovative biotechnology company, they are committed to developing groundbreaking therapeutics that can benefit patients worldwide. Through strategic partnerships and telemedicine models, Gossamer Bio is working to improve healthcare and insurance to ensure that everyone in the world has access to top-quality therapeutics to improve their health.
The expected revenue of Gossamer Bio is 35.86 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Gossamer Bio is -44.62 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Gossamer Bio is currently -0.68. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Gossamer Bio stock.
The price-to-sales ratio (P/S) of Gossamer Bio is currently 0.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Gossamer Bio stock.
The Eulerpool Quality Score for Gossamer Bio is 3/10.
The ISIN of Gossamer Bio is US38341P1021. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Gossamer Bio is A2PCBS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Gossamer Bio is GOSS. The ticker symbol is used to trade Gossamer Bio shares on the stock exchange.
Gossamer Bio stock
Gossamer Bio Peer Group
Gossamer Bio Ticker
Gossamer Bio FIGI
All fundamentals and in-depth analysis of Gossamer Bio
Our stock analysis for Gossamer Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gossamer Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.